Sophie Carter1, Zhuo Li2, Isabelle Lemieux2, Natalie Alméras3, Angelo Tremblay3, Jean Bergeron4, Paul Poirier1, Yves Deshaies5, Jean-Pierre Després3, Frédéric Picard6. 1. Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada; Faculty of Pharmacy, Université Laval, Québec, QC, Canada. 2. Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada. 3. Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada; Department of Kinesiology, Faculty of Medicine, Université Laval, Québec, QC, Canada. 4. Lipid Research Center, CHU de Québec Research Center, Québec, QC, Canada. 5. Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada; Department of Medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada. 6. Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada; Faculty of Pharmacy, Université Laval, Québec, QC, Canada. Electronic address: frederic.picard@criucpq.ulaval.ca.
Abstract
OBJECTIVE: To assess whether plasma IGFBP-2 is independently associated with components of the lipoprotein-lipid profile and to suggest a cutoff value that could identify subjects with the features of the metabolic syndrome. METHODS: In this cross-sectional study, 379 Caucasian men from the general population and covering a wide range of BMI were recruited through the media. Subjects with type 2 diabetes, BMI values > 40 kg/m(2), or taking medication targeting glucose or lipid metabolism or blood pressure were excluded. Anthropometric data were collected and plasma IGFBP-2 concentrations, glucose tolerance and an extensive plasma lipid profile were determined after an overnight fast. RESULTS: Subjects with low IGFBP-2 levels were characterized by increased fat mass (p < 0.0001), impaired insulin sensitivity (p < 0.0001) and higher plasma triglyceride (TG) levels (p < 0.0001). When divided into 6 quantiles, only subjects with the highest IGFBP-2 levels (>221.5 ng/mL) did not meet the NCEP ATP III criteria for the clinical diagnosis of the metabolic syndrome. In addition, circulating IGFBP-2 levels were significantly associated with VLDL-TG (r = -0.51, p < 0.0001) and HDL-C (r = -0.27, p < 0.0001) levels. After adjustments, plasma IGFBP-2 was found to be independently associated with VLDL-TG levels but not with HDL-C concentrations. CONCLUSIONS: In our cohort, IGFBP-2 levels <221.5 ng/mL are incrementally associated with a detrimental plasma lipoprotein-lipid profile. After adjustment for covariates, IGFBP-2 remained independently associated with VLDL-TG but not HDL-C levels. This study supports further investigations in other populations and validation of IGFBP-2 as a biomarker of early dyslipidemia.
OBJECTIVE: To assess whether plasma IGFBP-2 is independently associated with components of the lipoprotein-lipid profile and to suggest a cutoff value that could identify subjects with the features of the metabolic syndrome. METHODS: In this cross-sectional study, 379 Caucasian men from the general population and covering a wide range of BMI were recruited through the media. Subjects with type 2 diabetes, BMI values > 40 kg/m(2), or taking medication targeting glucose or lipid metabolism or blood pressure were excluded. Anthropometric data were collected and plasma IGFBP-2 concentrations, glucose tolerance and an extensive plasma lipid profile were determined after an overnight fast. RESULTS: Subjects with low IGFBP-2 levels were characterized by increased fat mass (p < 0.0001), impaired insulin sensitivity (p < 0.0001) and higher plasma triglyceride (TG) levels (p < 0.0001). When divided into 6 quantiles, only subjects with the highest IGFBP-2 levels (>221.5 ng/mL) did not meet the NCEP ATP III criteria for the clinical diagnosis of the metabolic syndrome. In addition, circulating IGFBP-2 levels were significantly associated with VLDL-TG (r = -0.51, p < 0.0001) and HDL-C (r = -0.27, p < 0.0001) levels. After adjustments, plasma IGFBP-2 was found to be independently associated with VLDL-TG levels but not with HDL-C concentrations. CONCLUSIONS: In our cohort, IGFBP-2 levels <221.5 ng/mL are incrementally associated with a detrimental plasma lipoprotein-lipid profile. After adjustment for covariates, IGFBP-2 remained independently associated with VLDL-TG but not HDL-C levels. This study supports further investigations in other populations and validation of IGFBP-2 as a biomarker of early dyslipidemia.
Authors: Nobuto Kaneko; Meredith L Journey; Chrys M Neville; Marc Trudel; Brian R Beckman; Munetaka Shimizu Journal: Fish Physiol Biochem Date: 2019-07-11 Impact factor: 2.794
Authors: Amy E Mendham; Lisa K Micklesfield; Fredrik Karpe; Andre Pascal Kengne; Tinashe Chikowore; Clement N Kufe; Maphoko Masemola; Nigel J Crowther; Shane A Norris; Tommy Olsson; Sölve Elmståhl; Tove Fall; Lars Lind; Julia H Goedecke Journal: Diabetologia Date: 2022-09-17 Impact factor: 10.460
Authors: Kirstine J Belongie; Ele Ferrannini; Kjell Johnson; Patricia Andrade-Gordon; Michael K Hansen; John R Petrie Journal: PLoS One Date: 2017-08-28 Impact factor: 3.240
Authors: Emer R McGrath; Jayandra J Himali; Daniel Levy; Sarah C Conner; Charles S DeCarli; Matthew P Pase; Paul Courchesne; Claudia L Satizabal; Ramachandran S Vasan; Alexa S Beiser; Sudha Seshadri Journal: Ann Clin Transl Neurol Date: 2019-08-02 Impact factor: 4.511